Novo Nordisk has significantly reduced the prices of its popular drugs Ozempic and Wegovy in India, responding to increasing competition in the GLP-1 market. The price cuts, effective April 1, see Ozempic reduced by 36% and Wegovy by 48%, a move designed to broaden patient access.
This decision comes as Indian pharmaceutical companies begin launching generic versions of semaglutide, the active ingredient in these medications, following the expiration of key patents. The increased competition is expected to drive down costs and make these treatments more accessible to individuals managing diabetes and obesity.
The price reduction reflects Novo Nordisk’s strategy to maintain market share amid growing competition. By lowering the cost of Ozempic and Wegovy, the company aims to make these therapies more affordable for a larger segment of the population in India.
The launch of generic semaglutide by Indian companies marks a significant shift in the market dynamics, potentially leading to further price adjustments and increased availability of these medications. This could have a substantial impact on the treatment landscape for diabetes and obesity in India.
About the Author
